SCHEDULE: Universe Pharmaceuticals: Gang Lai Boosts Stake to 13.58%

Gang Lai, CEO and Chairman of Universe Pharmaceuticals, has increased his beneficial ownership to 13.58% through direct holdings and a controlled entity, following an equity grant.

Summary

• Gang Lai, CEO and Chairman of Universe Pharmaceuticals INC, has increased his beneficial ownership of the company's Class A ordinary shares to 13.58%.
• This increase is a result of an equity grant received on May 7, 2026, which included 71,890 Class A ordinary shares and 12,610 Class B ordinary shares, awarded for past services.
• Additionally, Sununion Holding Group Limited, a company controlled by Gang Lai, holds 3,467 Class B ordinary shares.
• The total beneficial ownership comprises 71,890 Class A shares directly held, 12,610 Class A shares issuable from directly held Class B shares, and 3,467 Class A shares issuable from Class B shares held by Sununion Holding Group Limited.
• The filing indicates that Gang Lai intends to maintain his holding but may acquire additional shares or dispose of existing ones.
• The beneficial ownership percentage is calculated based on 631,761 Class A ordinary shares outstanding as of the filing date, plus shares issuable upon conversion of convertible securities.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it confirms a significant stake held by key management, indicating commitment, but does not present new operational or financial performance data.

Positives

• Gang Lai, a key executive, has increased his stake, potentially signaling confidence in the company's future.
• The equity grant was for past services, indicating recognition of contributions.
• The total beneficial ownership of 13.58% represents a significant stake held by the CEO and Chairman.

Negatives

• The filing does not explicitly detail any negative financial or operational performance.
• The potential for future share sales by Gang Lai could introduce downward pressure on the stock price.

Risks

• Gang Lai may acquire additional shares or sell/dispose of any or all of his beneficially owned shares, which could impact market price.
• The calculation of beneficial ownership percentage relies on the number of outstanding shares and convertible securities, which could fluctuate.

Future Outlook

Gang Lai intends to maintain his current holding in Universe Pharmaceuticals INC but reserves the right to acquire additional shares or sell/dispose of any or all of his beneficially owned shares at any time.

Management Comments

• Gang Lai may engage in communications with the Issuer's Board of Directors, members of management, other shareholders, financial and legal advisers, and other parties regarding the Issuer, including but not limited to the Issuer's operations, governance and control.
• Gang Lai may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.
• Gang Lai acquired the ordinary shares pursuant to the Equity Grant and intends to maintain his holding in the Issuer on a continuing basis.

Industry Context

StockSavvy.ai notes that significant stake increases by key executives in publicly traded companies, especially following equity grants, can be interpreted as a positive signal of management's commitment and belief in the company's prospects within the pharmaceutical sector.

Related Party Transactions

• Equity grant of 71,890 Class A ordinary shares and 12,610 Class B ordinary shares to Gang Lai for past services rendered.

Stakeholder Impact

• Shareholders: Increased alignment of interest with CEO/Chairman due to higher beneficial ownership. Potential for share price volatility if Gang Lai decides to sell shares.
• Employees: May view the equity grant as a positive sign of management's long-term commitment and recognition of contributions.
• Management: Reinforces Gang Lai's significant influence and stake in the company.

Next Steps

• Gang Lai may acquire additional shares of the Issuer.
• Gang Lai may sell or otherwise dispose of any or all of the shares that he beneficially owns.

Key Dates

Recommendation

This filing is primarily an update on beneficial ownership following an equity grant and does not contain new financial results, strategic shifts, or significant operational news that would warrant a change in investment recommendation. The increase in stake by the CEO is positive but expected given the equity grant. Investors should continue to monitor the company's performance and strategic execution.

Keywords

Universe Pharmaceuticals, Schedule 13D, Gang Lai, Sununion Holding Group Limited, Class A ordinary shares, Class B ordinary shares, beneficial ownership, equity grant, CEO, Chairman